65.53USD+1.28%Mkt Cap: 437.35M USDP/E: —Last update: 2026-06-01
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational onc…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap437.35M USD
Enterprise Value298.44M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.72M USD
Revenue/Share—
Last Price65.53 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS61023L1089
Valuation
P/E (Trailing)—
P/E (Forward)-20.21
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B3.16
EPS (TTM)-1.93
EPS (Forward)-3.22
52W Range
28.4048% of range105.00
52W High105.00 USD
52W Low28.40 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-9.95%
ROA-9.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.20M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.23%
Net Debt-137.26M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio56.05
Quick Ratio55.94
Book Value/Sh20.59 USD
Cash/Share20.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 13, 2024
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)112.62 USD
Target Range100.00 USD – 130.00 USD
# Analysts13
Ownership
Shares Out.6.70M
Float4.13M
Insiders23.23%
Institutions93.27%
Short Interest
Short Ratio8.9d
Short % Float34.31%
Short % Out.23.42%
Shares Short1.57M
Short (prev mo.)1.72M
Technical
SMA 5057.36 (+14.2%)
SMA 20064.50 (+1.6%)
Beta1.50
S&P 52W Chg27.94%
Avg Vol (30d)167.44K
Avg Vol (10d)217.34K
Technical Indicators
RSI (14)58.2
MACD1.9575
MACD Signal1.5573
MACD Hist.+0.4001
BB Upper68.75 USD
BB Middle61.04 USD
BB Lower53.32 USD
BB Width25.28%
ATR (14)4.722 USD
Vol Ratio (20d)0.54x